Loading…
Employees: 645
Size Peptidream (4587.T) is a Japan Health Care company (Biotechnology) with a market value of $856M, the 810th largest of 1,379 Japan companies the cockpit tracks. Shares closed at ¥1,039 on 6 Nov 2026.
Performance Over six months the shares fell 9.7%, against -19.9% for the median peer and +1.8% for the Japan market (cap-weighted) — 5th highest of 19 in its peer set.
Growth Revenue grew 0.6% over the last twelve months (peer median -1.8%); the operating margin is -25.3% (peer median -24.3%).
Valuation It trades at 20.0× forward earnings against a peer median of 35.8× (2nd cheapest of 6).
Capital Return on invested capital runs 13.3 points below its cost of capital (5.0% WACC).
Next results Next results expected around 11 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥19.2B | ¥18.5B | ¥46.7B | ¥28.7B | ¥26.9B |
| Revenue growth | — | -60% | +63% | +7% | — |
| Gross profit | ¥8.32B | ¥7.20B | ¥34.2B | ¥16.9B | ¥17.8B |
| EBITDA | -¥2.82B | -¥2.85B | ¥23.6B | ¥9.61B | ¥11.3B |
| Net income | -¥3.63B | -¥3.75B | ¥15.0B | ¥3.04B | ¥7.55B |
| Free cash flow | -¥5.56B | -¥15.0B | ¥21.8B | ¥11.2B | -¥4.02B |
| Capital expenditure | ¥1.40B | ¥1.75B | ¥2.22B | ¥1.37B | ¥3.98B |
| Total debt | ¥15.7B | ¥19.5B | ¥20.4B | ¥22.8B | ¥21.7B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4587.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.8% | -7.0% | 8th highest of 21 |
| 6-month return | -9.7% | -19.9% | 5th highest of 19 |
| Distance from 52-week high | -42.0% | -43.9% | 10th highest of 21 |
| Revenue growth (TTM) | +0.6% | -1.8% | 8th highest of 17 |
| Operating margin | -25.3% | -24.3% | 9th lowest of 18 |
| Forward P/E | 20.0× | 35.8× | 2nd cheapest of 6 |
| ROIC minus cost of capital | -13.3 pp | -15.2 pp | 7th highest of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Peptidream 4587.T | Japan | $856M | -10% | +1% | -25% | 20.0× | n/a | n/a |
| Syndax Pharmaceuticals SNDX | United States | $859M | -56% | +160% | -62% | n/a | n/a | n/a |
| MeiraGTx MGTX | United States | $864M | -8% | +948% | 46% | n/a | -9.9% | +39.2% |
| GNI 2160.T | Japan | $866M | -29% | +10% | -24% | 135.6× | n/a | n/a |
| Prime Medicine PRME | United States | $843M | +45% | -18% | -4,825% | n/a | n/a | n/a |
| Oxford BioMedica OXB.L | United Kingdom | $892M | -14% | +16% | -18% | n/a | n/a | n/a |
| Wuhan Keqian Biology 688526.SS | China | $814M | -19% | -22% | 20% | 16.6× | 8.8% | +2.4% |
| Monte Rosa Therapeutics GLUE | United States | $902M | -45% | -84% | -633% | n/a | n/a | n/a |
| R&G PharmaStudies 301333.SZ | China | $803M | -12% | +21% | 11% | 38.4× | 20.1% | +11.8% |
| Anhui Wanbang Pharmaceutical Technology 301520.SZ | China | $803M | +91% | -15% | -8% | n/a | 48.8% | +14.7% |
| Inventiva IVA.PA | France | $912M | -29% | -100% | -307,063% | n/a | n/a | n/a |
| Beijing SL Pharmaceutical 002038.SZ | China | $793M | -21% | -4% | -119% | n/a | -12.3% | -10.9% |
| Odyssey Therapeutics ODTX | United States | $924M | n/a | -33% | -5,415% | n/a | n/a | n/a |
| Nanjing Leads Biolabs 9887.HK | Hong Kong | $927M | -54% | n/a | -108% | n/a | n/a | n/a |
| Alphamab Oncology 9966.HK | Hong Kong | $777M | -39% | -32% | -38% | n/a | n/a | n/a |
| Shaanxi Micot Pharmaceutical Technology 2335.HK | Hong Kong | $777M | n/a | n/a | n/a | n/a | n/a | n/a |
| Jade Biosciences JBIO | United States | $958M | -42% | n/a | n/a | n/a | n/a | n/a |
| China Animal Husbandry Industry 600195.SS | China | $960M | -17% | +1% | 2% | 35.8× | 6.6% | +4.4% |
| Frontier Biotechnologies 688221.SS | China | $746M | -37% | +153% | -20% | n/a | 43.2% | +21.5% |
| Alto Neuroscience ANRO | United States | $987M | +4% | n/a | n/a | n/a | n/a | n/a |
| Chengdu Kanghua Biological Products Co. Td Class 1 300841.SZ | China | $995M | -11% | 0% | 22% | 23.6× | 11.1% | +2.3% |